Clinical significance of antiproteinase 3 antibody positivity in cANCA-positive patients

被引:12
作者
van Pesch, V [1 ]
Jadoul, M [1 ]
Lefèbvre, C [1 ]
Lauwerys, BR [1 ]
Tomasi, JP [1 ]
Devogelaer, JP [1 ]
Houssiau, FA [1 ]
机构
[1] Univ Catholique Louvain 5390, Dept Rheumatol, B-1200 Brussels, Belgium
关键词
activity; ANCA; antiproteinase; 3; serology; vasculitis;
D O I
10.1007/s100670050102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We addressed the clinical significance of antiproteinase 3 (anti-PR3) antibody (Ab) positivity by reviewing the files of 79 patients whose serum contained antineutrophil cytoplasmic antibodies with a cytoplasmic staining pattern (cANCA) and had been tested for anti-PR3 reactivity, Vasculitis was present in most (22/35) cANCA(+) PR3(+) patients but in only a few (5/44) cANCA(+) PR3(-) patients, thereby suggesting that anti-PR3 Ab positivity in cANCA(+) patients is more indicative of vasculitis than cANCA positivity alone. Noteworthy, one-third of cANCA(+) PR3(+) patients - those with anti-PR3 Ab titres lower than 100 U/ml - did not suffer from vasculitis. Anti-PR3 reactivity in vasculitis patients was only weakly associated with Wegener's granulomatosis (WG), as nine out of 22 cANCA(+) PR3(+) vasculitis patients (41%) did not fulfil the ACR classification criteria for WG. There was no correlation between anti-PR3 Ab titres and disease activity at diagnosis. However, titres measured when patients were in remission were much lower than initial values. Taken together, our results indicate that anti-PR3 Ab positivity should be interpreted in its clinical context.
引用
收藏
页码:279 / 282
页数:4
相关论文
共 16 条
[1]   PITFALLS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) [J].
DECLERCK, LS ;
VANOFFEL, JF ;
SMOLDERS, WA ;
EMPSTEN, FA ;
BRIDTS, CH ;
BOURGEOIS, N ;
VANMARCK, E ;
TIMMERMANS, U ;
STEVENS, WJ .
CLINICAL RHEUMATOLOGY, 1989, 8 (04) :512-516
[2]  
GASKIN G, 1993, ADV EXP MED BIOL, V336, P287
[3]  
GEFFRIAUDRICOUARD C, 1993, CLIN NEPHROL, V39, P125
[4]   Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis [J].
Hagen, EC ;
Daha, MR ;
Hermans, J ;
Andrassy, K ;
Csernok, E ;
Gaskin, G ;
Lesavre, P ;
Lüdemann, J ;
Rasmussen, N ;
Sinico, RA ;
Wiik, A ;
van der Woude, FJ .
KIDNEY INTERNATIONAL, 1998, 53 (03) :743-753
[5]  
Hoffman GS, 1998, CLIN EXP RHEUMATOL, V16, P111
[6]   WEGENER AUTOANTIGEN DECODED [J].
JENNE, DE ;
TSCHOPP, J ;
LUDEMANN, J ;
UTECHT, B ;
GROSS, WL .
NATURE, 1990, 346 (6284) :520-520
[7]   NOMENCLATURE OF SYSTEMIC VASCULITIDES - PROPOSAL OF AN INTERNATIONAL CONSENSUS CONFERENCE [J].
JENNETTE, JC ;
FALK, RJ ;
ANDRASSY, K ;
BACON, PA ;
CHURG, J ;
GROSS, WL ;
HAGEN, EC ;
HOFFMAN, GS ;
HUNDER, GG ;
KALLENBERG, CGM ;
MCCLUSKEY, RT ;
SINICO, RA ;
REES, AJ ;
VANES, LA ;
WALDHERR, R ;
WIIK, A .
ARTHRITIS AND RHEUMATISM, 1994, 37 (02) :187-192
[8]  
JENNINGS JG, 1994, CLIN EXP IMMUNOL, V95, P251
[9]   LIMITED PROGNOSTIC VALUE OF CHANGES IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY TITER IN PATIENTS WITH WEGENER GRANULOMATOSIS [J].
KERR, GS ;
FLEISHER, TA ;
HALLAHAN, CW ;
LEAVITT, RY ;
FAUCI, AS ;
HOFFMAN, GS .
ARTHRITIS AND RHEUMATISM, 1993, 36 (03) :365-371
[10]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY 1990 CRITERIA FOR THE CLASSIFICATION OF WEGENER GRANULOMATOSIS [J].
LEAVITT, RY ;
FAUCI, AS ;
BLOCH, DA ;
MICHEL, BA ;
HUNDER, GG ;
AREND, WP ;
CALABRESE, LH ;
FRIES, JF ;
LIE, JT ;
LIGHTFOOT, RW ;
MASI, AT ;
MCSHANE, DJ ;
MILLS, JA ;
STEVENS, MB ;
WALLACE, SL ;
ZVAIFLER, NJ .
ARTHRITIS AND RHEUMATISM, 1990, 33 (08) :1101-1107